- Report
- October 2024
- 193 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 90 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 269 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2023
- 210 Pages
Global
From €1892EUR$1,990USD£1,589GBP
- Report
- August 2023
- 370 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- July 2022
- 40 Pages
China
From €3042EUR$3,200USD£2,556GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- January 2024
- 250 Pages
Global
€4749EUR$4,995USD£3,989GBP
- Report
- September 2023
- 101 Pages
North America
From €2804EUR$2,950USD£2,356GBP
- Report
- November 2022
- 160 Pages
Global
€3232EUR$3,400USD£2,715GBP
- Report
- September 2020
- 55 Pages
United States
From €1226EUR$1,290USD£1,030GBP
The Shingles Vaccine is a vaccine used to prevent shingles, a painful skin condition caused by the varicella-zoster virus. It is recommended for adults over the age of 50, and is available in both single-dose and two-dose formulations. The vaccine is typically administered by a healthcare provider, and is available in both private and public healthcare settings.
The Shingles Vaccine market is a subset of the larger Vaccines market, which is estimated to be worth billions of dollars. The Shingles Vaccine market is expected to grow in the coming years, driven by an aging population and increased awareness of the condition.
Some of the major companies in the Shingles Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and AstraZeneca. Show Less Read more
